Author/Editor		Težak, Stanko; Ostojić, Rajko; Perković, Zdravko; Rustemović, Nadan; Car, Nikica; Papa, Branko; Poropat, Mirjana; Dodig, Damir
Title		Indium-111-DTPA-octreotide scintigraphy in patients with carcinoid tumor
Translated title		Scintigrafija z indij-111-DTPA-oktreotidom pri bolnikih s karcinoidom
Type		članek
Source		Radiol Oncol
Vol. and No.		Letnik 33, št. 4
Publication year		1999
Volume		str. 315-20
Language		eng
Abstract		Background. The aim of the study was the evaluation of clinical utility and comparison of 111 In-DTPA- octreotide receptor scintigraphy (SRS) with conventional imaging modalities (CIM) in the detection of carcinoid tumor. Patients and methods. Fourteen patients with pathohistologically proven diagnosis of carcinoid tumor and one patient with clinical suspicion of carcinoid tumor were investigated by SRS. SRS was performed for localization of primary tumor, recurrence or estimation of spread of the disease after CIM had been completed. Whole body scans and single photon emission computed tomography (SPECT) were acquired 6 and 24 h after the application of radiopharmaceutical. The intensity of nonspecific radiopharmaceutical uptake in the bowel was assessed semiquantitatively by a score using whole body scans. Results. The evaluation was done for patients and for tumor sites. The sensitivity, specificity, and positive and negative predictive values for patient evaluation were 89 %,100 %,100 % and 80 %, respectively for both CIM and SRS, whereas for tumor sites, these parameters were 69 % 100 %,100 % and 82 % for CIM, and 88%,100%,100% and 92 % for SRS. Intensity score of nonspecific 111In-octreotide bowel accumulation was 0.92 and 2.01 for 6 and 24 h scans respectively (p < 0.01). Conclusion. 111In-octreotide scintigraphy should be included in the diagnostic algorithm for the patients with clinical suspicion of carcinoid and for the assessment of patients with proven carcinoid tumor.
Summary		Izhodišča. Študijo smo izvedli z namenom, da ocenimo klinično uporabnost scintigrafije somatostatinskih receptorjev z indij-111-DTPA-oktreotidom (SRS) ter jo primerjamo s konvencionalnimi načini slikovne preiskave pri bolnikih s karcinoidom. Bolniki in metode. Štirinajst bolnikov s patohistološko potrjenim karcinoidom in enega bolnika s klinično ugotovljenim karcinoidom smo preiskali s SRS. Preiskavo SRS smo izvedli po konvencionalni slikovni preiskavi in z njo poskušali lokalizirati primarni tumor in ugotoviti ponovitev ali razsoj bolezni. Scintigrafijo celotnega telesa in računalniško tomografijo z emisijo posameznih elektronov (SPECT) smo opravili 6 in 24 ur po vbrizganem radiofarmacevtskem sredstvu. Intenzivnost nespecifičnega kopičenja radiofarmacevtskega sredstva v črevesu smo ocenili semikvantitativno s scintigrafijo celotnega telesa. Rezultati. Intenzivnost kopičenja smo ocenili glede na bolnike in glede na lokalizacijo tumorja. Pri bolnikih je občutljivost znašala 89%, specifičnost 100%, pozitivne in negativne napovedne vrednosti pa so bile 100% in 80% tako pri konvencionalnem načinu slikovne preiskave kot pri SRS. Pri ocenjevanju lokalizacije tumorja so bili zgornji parametri naslednji: slikanje celotnega telesa: občutljivost 69%, specifičnost 100%, pozitivne in negativne napovedne vrednosti 100% in 82%; SRS: občutljivost 88%, specifičnost 100%, pozitivne in negativne napovedne vrednosti 100% in 92%. Intenzivnost nespecifičnega kopičenja 111-indija-oktreotida v črevesju je bila pri slikah, posnetih po 6. urah 0,92 in pri slikah, posnetih po 24 urah, 2,01 (p < 0,01). Zaključki. SRS bi morala biti vključena v diagnostični algoritem pri bolnikih, pri katerih je bil karcionoid ugotovljen le klinično in tudi pri bolnikih s potrjeno diagnozo karcionoida.
Descriptors		CARCINOID TUMOR INDIUM RADIOISOTOPES OCTREOTIDE DTPA INTESTINAL NEOPLASMS LIVER NEOPLASMS TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON